0R3M.LSE Vivoryon Therapeutics N.V.
- Market cap
- EUR 17.0M
- P/E
- -
- P/B
- -
- ROE
- -865.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0R3M.LSE undervalued?
Graham numberThe Graham number of Vivoryon Therapeutics N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vivoryon Therapeutics N.V. fundamental analysis
No fundamental analysis for Vivoryon Therapeutics N.V. yet.
Vivoryon Therapeutics N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company i…
Full company profileVivoryon Therapeutics N.V. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vivoryon Therapeutics N.V. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 10.8M | - | -3.62M | - | - | - |
| Gross Profit | -97.0K | -106K | -23.0K | -88.0K | -146K | 9.03M | -161K | -4.15M | -147K | -147K | -268K |
| Operating Income | -13.9M | -9.97M | -7.73M | -7.77M | -16.0M | -12.8M | -29.1M | -28.8M | -21.0M | -9.18M | -13.6M |
| EBITDA | -13.7M | -9.86M | -7.68M | -7.63M | -16.3M | -12.0M | -28.2M | -28.1M | -20.3M | -9.03M | -13.3M |
| Net Income | -13.9M | -8.01M | -7.74M | -7.82M | -16.5M | -12.7M | -28.2M | -28.3M | -20.6M | -8.85M | -13.6M |
| EPS | -1.79 | -0.96 | -0.92 | -0.62 | -0.83 | -0.63 | -1.28 | -1.12 | -0.79 | -0.33 | -0.46 |
| Balance Sheet | |||||||||||
| Total Assets | 22.4M | 10.8M | 4.05M | 45.9M | 29.8M | 24.5M | 31.4M | 30.8M | 11.3M | 7.52M | 4.17M |
| Total Liabilities | 5.99M | 1.84M | 2.82M | 3.20M | 3.53M | 7.96M | 4.87M | 4.55M | 3.40M | 2.79M | 2.60M |
| Shareholders' Equity | 16.4M | 8.92M | 1.23M | 42.7M | 26.2M | 16.6M | 26.5M | 26.3M | 7.88M | 4.73M | 1.57M |
| Cash & Short-term Investments | 21.9M | 10.3M | 3.78M | 41.5M | 26.3M | 14.7M | 26.6M | 28.6M | 9.37M | 5.62M | 2.45M |
| Total Debt | - | - | - | 406K | 314K | 224K | 132K | 38.0K | 102K | 108K | 76.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.3M | -12.1M | -6.99M | -11.6M | -14.0M | -11.3M | -21.8M | -21.5M | -19.2M | -8.46M | -12.6M |
| Capital Expenditure | 124K | 8.00K | 16.0K | 47.0K | 640K | 28.0K | 13.0K | 14.0K | 2.00K | 6.00K | 0.00 |
| Free Cash Flow | -13.4M | -12.1M | -7.01M | -11.7M | -14.7M | -11.3M | -21.8M | -21.6M | -19.2M | -8.46M | -12.6M |
| Ratios | |||||||||||
| ROE | -84.8% | -89.8% | -629.0% | -18.3% | -63.0% | -76.4% | -106.2% | -107.8% | -261.0% | -187.3% | -865.9% |
| ROA | -62.1% | -74.4% | -191.1% | -17.1% | -55.5% | -51.6% | -89.7% | -91.9% | -182.3% | -117.8% | -325.2% |
| Net Profit Margin | - | - | - | - | - | -117.6% | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.02x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vivoryon Therapeutics N.V. dividends
Vivoryon Therapeutics N.V. has not paid dividends in the last 9 fiscal years.
Who owns Vivoryon Therapeutics N.V.
- Insiders 4.85%
- Institutions 8.85%
- Public & others 86.30%
- Shares outstanding 8.21M
- Free float 26.3M
Vivoryon Therapeutics N.V. company profile
- Company name
- Vivoryon Therapeutics N.V.
- Ticker
- 0R3M.LSE
- ISIN
- NL00150002Q7
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- Weinbergweg 22, Halle, Germany, 06120
- Phone
- 49 345 55599-00
- Website
- vivoryon.com
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Vivoryon Therapeutics N.V. management
7- Dr. Frank T. Weber M.D.MD, CEO, Chief Medical Officer & Executive Director · born 1960
- Mr. Marcus IrsfeldCFO & Executive Director · born 1966
- Dr. Julia Neugebauer Ph.D.Head of Investor Relations & Communications, COO & Executive Board Member · born 1979
- Dr. Michael Schaeffer Ph.D.Chief Business Officer & Executive Director · born 1969
- Dr. Manuela BaderDirector of Investor Relations & Communications
- Dr. Konrad GlundCo-Founder & Advisor · born 1953
- Dr. Hendrik LiebersAdvisor · born 1971